AbstractBackgroundCognitive decline with aging and neurodegeneration is caused by various neurobiological processes at molecular, cellular, and organ levels. Advanced imaging techniques that detect tissue microstructural alterations may predict cognitive decline earlier than atrophy measures. Tissue‐level mechanical properties are thought to primarily reflect the rigidity and tension of extracellular matrix‐cytoskeleton matrix (https://doi.org/10.1038/s41586‐019‐1516‐5) and can be measured noninvasively by Magnetic Resonance Elastography (MRE) (https://doi.org/10.1126/science.7569924). These properties are sensitive to pathophysiological processes that characterize neurological disease including dementias. This study examines the role of medial temporal lobe stiffness in predicting global cognitive decline in participants along the Alzheimer’s disease spectrum.MethodSeventy‐five participants underwent MRE, MRI, amyloid PET imaging, and cognitive assessments with informed consent, and the study was approved by the Mayo Clinic IRB. MRE stiffness maps were calculated by neural network inversion, and medial temporal (MT) stiffness extracted (https://doi.org/10.1002/mrm.29226https://doi.org/10.1016/j.nicl.2023.103328). White matter hyperintensity (WMH) load, average cortical thickness of AD signature regions, PiB‐PET standardized uptake ratio (PiB‐SUVr), and global cognition z‐scores were each computed (https://doi.org/10.1016/j.neurobiolaging.2020.09.005). Linear mixed effect models were used to assess the effects of MT‐stiffness and its interaction with follow‐up time on global cognition. The additional effects of cortical thickness, WMH, and PiB‐SUVr, and their interactions with cognition follow‐up time were evaluated.ResultTable 1 summarizes results from three mixed effect models. MT‐stiffness and its interaction with time were significant predictors in models 1 (MT‐stiffness only) and 2 (MT‐stiffness+cortical thickness). In model 3 (MT‐stiffness+cortical thickness+PiB‐ratio+WMH), MT‐stiffness alone did not reach significance (P= 0.058), but its interaction with time was a significant predictor. Fig.1 shows global cognition z‐scores with age. Figs. 2A,2B, and 2C show global cognition prediction trajectories. These results suggest that softer MT‐stiffness predicts faster cognitive decline. MT‐stiffness was a significant predictor of cognitive score even when controlling for other biomarkers such as cortical thickness, PiB‐SUVr, and WMH. These results indicate that stiffness measurements can add predictive value regarding cognitive decline in addition to atrophy and amyloidosis.ConclusionBrain mechanical alterations capture microstructural changes that may aid in understanding disease progression and provide information about future cognitive decline in elderly participants along the Alzheimer’s disease continuum.
Effects of de‐facing T1 MRI, FLAIR MRI, Amyloid PET, and Tau PET scans on imaging‐clinical correlations analyses
AbstractBackgroundAutomated face recognition can potentially re‐identify de‐identified research brain MRI, PET, and CT, and direct differences of brain measurements from original and de‐faced images are statistically significant but very minor, i.e. below scan‐rescan differences. Their effects on analyses correlating brain imaging biomarkers with clinical variables remain unknown.MethodWe sampled 3 age‐and‐sex‐matched groups (CU, MCI, and clinical AD) from Mayo Clinic aging studies, each with 61 participants with same‐visit 3D T1‐weighted and 3D T2‐FLAIR MRI, PiB amyloid PET, and Flortaucipir tau PET (total n = 183). We automatically measured hippocampal volume, PIB global SUVR, and tau temporal meta‐ROI SUVR using a) our in‐house pipeline with SPM12, MCALT, and ANTs, and b) FreeSurfer 7.3.2 (PETSurfer), and we measured voxels associated with clinical group separation using SPM12. We also measured WMH from FLAIR using a) our in‐house pipeline, b) Lesion Segmentation Tool (LST), and c) FreeSurfer’s Samseg. For each measurement, we calculated pair‐wise group separation AUC values and Spearman’s rho with age and CDR‐SOB. We then de‐faced all PET and MRI using mri_reface, our top‐performing automated de‐facing software that replaces imaged faces with an average face (“re‐facing”), and we repeated all measurements and analyses with de‐faced images. We then compared the magnitudes of clinical correlations with original images and those of de‐faced images.ResultAnalyses of original and de‐faced images had very high agreement. Only 2/55 paired comparisons were significant (Tables 1‐2): FreeSurfer‐measured global PIB SUVR from de‐faced images was more correlated with age (rho 0.003 vs ‐0.227, p = 0.046), and Mayo‐measured WMH volume from original images was more correlated with CDR‐SOB (rho 0.321 vs 0.308, p = 0.020). Another comparison‐pair tested p = 0.041 for an AUC change +0.008, which we consider not practically meaningful. All others had p>0.05. In voxel‐based analyses of CU vs AD participants, all comparisons were qualitatively similar between original and de‐faced variants (Figure 1).ConclusionDe‐facing PET and MRI using mri_reface did not significantly affect 53/55 correlations between imaging and clinical variables; of the two affected, one became stronger with re‐faced images. Stronger correlations with clinical variables may be explained by de‐facing’s standardizing face voxels and artifacts that irrelevantly affect brain segmentations.
Comparison of longitudinal rates of atrophy and tau accumulation between posterior cortical atrophy and logopenic progressive aphasia
AbstractBackgroundPosterior cortical atrophy (PCA) and logopenic progressive aphasia (LPA) are atypical variants of Alzheimer’s disease which typically show different cross‐sectional patterns of atrophy and tau deposition. Patterns of atrophy remain distinct longitudinally. A direct comparison of rates of atrophy and tau accumulation between these syndromes has not yet been reported.MethodWe evaluated 20 PCA and 20 LPA patients; all were amyloid‐positive on [11C]PiB‐PET. Structural MRI and tau‐PET were performed at baseline and one‐year follow‐up. Annualized rates of change in grey matter volume (log Jacobians from tensor‐based morphometry) and flortaucipir‐PET SUVRs were calculated at the lobar level. A global tau SUVR was calculated using parietal, temporal, and occipital regions. Lobar rates were compared between PCA and LPA with linear models, accounting for education, sex, age, baseline global tau SUVR (for tau‐PET), with significance set at p = 0.05. SPM voxel‐level comparisons were performed, with the same covariates, with significance set at p = 0.001.ResultGroups did not differ in age, Apoe status, baseline global tau SUVR or whole brain volume, or their annualized rates of change. LPA had shorter disease duration. In the lobar models, PCA had faster rates of atrophy in the occipital lobe and there were no significant differences on rates of tau accumulation, but a trend for LPA having faster rates of tau accumulation in all lobes. Baseline global tau SUVR was negatively associated with rate of tau accumulation in parietal and temporal lobes. Age was negatively associated with rates of tau accumulation in frontal, temporal and occipital lobes and with rates of atrophy in frontal and parietal lobes. Voxel‐level analysis confirmed these results, with PCA showing faster rates of occipital atrophy, and LPA showing subtle evidence for diffuse faster rates of tau accumulation (Figure 1).ConclusionLongitudinal patterns of neuroimaging abnormalities differ between PCA and LPA, although with divergent results for tau accumulation and atrophy that may reflect differences in disease stage. Rates of change are strongly influenced by age and severity of baseline tau, with faster rates of tau accumulation in patients with younger age and lower baseline tau deposition.
Alzheimer’s disease biomarkers of amyloid and tau influence white matter neurite alterations in dementia with Lewy bodies: a NODDI study
AbstractBackgroundCo‐morbid Alzheimer’s disease (AD) pathology in the form of amyloid‐β plaques and tau neurofibrillary tangles are frequently observed in people with probable dementia with Lewy bodies (DLB). Neurite Orientation Dispersion and Density Imaging (NODDI) is an emerging technique to characterize white matter (WM) tissue microstructure, although NODDI alterations and associations with AD biomarkers remain undefined in DLB. The objectives of this study are to compare NODDI and DTI parameters between DLB and controls and (ii) evaluate the pattern of DTI and NODDI changes associated with amyloid and tau deposition.MethodConsecutive patients within the DLB spectrum (n = 45), including probable DLB (n = 32) and probable Mild Cognitive Impairment with Lewy bodies (MCI‐LB) (n = 13) from the Mayo Clinic ADRC underwent multi‐shell diffusion MRI, [18F]‐Flortaucipir and [11C]‐PiB PET. A comparison group of 45 age‐ and gender‐matched clinically unimpaired controls (CU) was included. Voxelwise non‐parametric permutation models were used to determine pair‐wise group differences and assess the associations of AD biomarkers with fractional anisotropy (FA), mean diffusivity (MD), tissue‐weighted neurite density index (tNDI; NDI x (1 – Free water fraction)) and orientation dispersion index (ODI), controlling for age. Complementary analyses were performed using regions‐of‐interest (ROI) obtained from the JHU atlas.ResultCompared to CU, the DLB spectrum group exhibited widespread decreases in FA and tNDI and increases in MD and ODI, with the most pronounced effects in the cingulum bundles, uncinate, inferior and superior longitudinal fasciculi (Fig. 1). Greater [18F]‐Flortaucipir uptake was also associated with lower FA and tNDI, and higher MD and ODI in the DLB spectrum compared to CU, independently of age and [11C]‐PiB uptake (Fig. 2). In contrast, no associations were found between [11C]‐PiB uptake and any of the DTI or NODDI parameters. Complementary ROI analyses corroborated these findings.ConclusionWidespread loss of WM integrity was observed on DTI and NODDI in probable DLB and prodromal DLB. These findings were associated with greater cortical tau, but not with amyloid‐β deposition. Although alpha‐synuclein pathology underlies the loss of WM integrity in DLB, amyloid‐independent tau pathology may also be an important influence on white matter integrity within the DLB spectrum.
Neurite‐based white matter alterations in MAPT mutation carriers: A multi‐shell diffusion MRI study in the ALLFTD consortium
AbstractBackgroundWe aimed to assess axonal integrity in MAPT mutation carriers and early white matter (WM) neurodegeneration in asymptomatic carriers using traditional diffusion tensor imaging (DTI) measurements, i.e., fractional anisotropy (FA) and mean diffusivity (MD), and neurite orientation dispersion and density imaging (NODDI).MethodWe included available multi‐shell diffusion MRI data from 21 MAPT mutation carriers (16 asymptomatic; 5 symptomatic) and 31 non‐carrier family members as controls from the ALLFTD consortium. We used linear mixed‐effect models to assess WM abnormalities measured with FA and MD, neurite density index (NDI) and orientation dispersion index (ODI), combined across hemispheres. Separate models were conducted in all MAPT mutation carriers relative to controls while accounting for relatedness and age, then in symptomatic and asymptomatic carriers relative to controls. ComBat was used to harmonize data across sites.ResultIn models contrasting all MAPT carriers versus controls, WM alterations involved the cingulum bundle (FA, ODI), fronto‐temporal, entorhinal (FA, MD, NDI), and the inferior temporal WM (FA) after correcting for multiple comparisons (Fig. 1). In models contrasting symptomatic and asymptomatic MAPT carriers versus controls, symptomatic carriers had widespread involvement of the fronto‐temporal WM including the cingulum (FA, ODI), entorhinal (MD, FA, NDI), amygdala (MD, NDI) and inferior temporal (FA) areas after correcting for multiple comparisons. Asymptomatic carriers showed higher entorhinal MD and lower inferior temporal and cingulum FA relative to controls, and a more widespread pattern of higher ODI involved the medial temporal, superior temporal and occipital WM as well as long association and projection fibers including the internal capsule, cingulate bundle and fronto‐occipital fasciculi, although they were not statistically significant after correction for multiple comparisons.ConclusionTraditional DTI and novel NODDI measurements revealed some extent of overlap as well as divergences in patterns of WM abnormalities, indicating axonal loss is a feature of neurodegeneration in MAPT mutation carriers. Our results suggest that traditional DTI and novel NODDI measurements may have different sensitivities to WM alterations in MAPT mutation carriers, and that axon‐based metrics, particularly ODI measurements, may be more sensitive to the early WM involvement during the asymptomatic stage of the disease.
Tangle and neuritic burden from neurofibrillary tangle maturity markers in the hippocampus are differentially correlated to tau‐PET, MRI, and cognitive measures
AbstractBackgroundThere is a gap in knowledge concerning which tangle maturity levels (Moloney, Alzheimers Dement, 2021) are associated with antemortem measures (tau‐PET, MRI, cognitive testing). We hypothesized antemortem measures would be more strongly correlated with markers recognizing middling to advanced tangle maturity. We additionally sought to assess the strength of the relationship with tangle and neuritic pathology recognized by tangle maturity markers.MethodPosterior hippocampi from n = 30 cases with antemortem measures ≤3 years prior to death were cut (5µm) and immunostained with tau antibodies to evaluate early (AT8), middling (PHF‐1), or advanced (2E9) tangle maturity. GENIE (pattern recognition software) separated tangle from neuritic burden (Figure). Hippocampus, parahippocampus, and fusiform were analyzed to correlate digital pathology with flortaucipir tau‐PET standard uptake value ratio (SUVr, cerebellar crus normalization), MRI volume/thickness, and cognitive measures which included Auditory Verbal Learning Test (AVLT) delayed recall, Mini‐Mental State Exam (MMSE), and Clinical Dementia Rating (CDR).ResultThe strongest relationships observed with flortaucipir were with PHF‐1 and 2E9 burden (Table). AT8 tangle and neuritic burden correlations with flortaucipir were relatively similar in the hippocampus but were stronger with neuritic pathology in parahippocampus and fusiform. PHF‐1 tangle and neuritic burden correlations were relatively similar with flortaucipir. 2E9 correlations were stronger with neuritic pathology in hippocampus. MRI measures were more strongly correlated with PHF‐1 and 2E9 burden. AT8 tangle and neuritic burden were correlated with fusiform thickness. The correlations between MRI measures and 2E9 tangle and neuritic burden were similar. Correlations between cognitive measures were similar between tangle maturity markers. AVLT delayed recall correlated with all tangle maturity markers, but neuritic burden was stronger for AT8 and 2E9 in hippocampus compared to tangle burden. MMSE correlated with neuritic burden for all tangle maturity markers. CDR remained statistically non‐significant.ConclusionInterpretation of the strength of the relationship between tau burden and antemortem measures differed across tangle maturity markers. Neuroimaging measures may be more sensitive to middle/advanced maturity markers with limited differences between tangle and neuritic pathology. These findings may be biologically relevant and imply either a limited recognition of tangles depending on antibody epitope, and/or may represent the clinicoradiologic impact of increasing neuritic burden.
Cross‐sectional comparison of the role of tau burden among Down Syndrome Alzheimer disease and autosomal‐dominant Alzheimer disease
AbstractBackgroundAdults with Down Syndrome (DS) develop Alzheimer disease (AD)‐like pathology and dementia as they age. This is attributed to triplication of the amyloid precursor protein gene. Recent work demonstrated that amyloid is elevated in DS and accumulates in a similar topography to autosomal dominant AD (ADAD). Tau accumulation is the second hallmark of AD and may be measured using tau positron emission tomography (PET) imaging. The pattern of tau accumulation remains unknown in DS.MethodIn a cross‐sectional analysis we evaluated amyloid and tau positron emission tomography (PET) in 124 participants with DS (109 cognitively stable, 8 symptomatic, 7 no consensus), 29 ADAD mutation carriers (26 asymptomatic, 3 symptomatic), and 201 cognitively normal non‐mutation carriers (CN). Regional cortical standard uptake value ratios (SUVR) for tau imaging were obtained and compared by cognitive status. Similarly, regional cortical amyloid SUVR were obtained and converted to centiloids. We then compared the magnitude of tau burden as well as spatial spread of tau across groups relative to amyloid burden.ResultCompared to CN, tau PET binding was elevated in participants with (µDS = 2.12 ± 0.22 SUVR, µADAD = 2.52 ± 0.37 SUVR) and without (µDS = 1.24 ± 0.15 SUVR, µADAD = 1.16 ± 0.19 SUVR) cognitive changes. For both groups, tau increased with increasing amyloid (centiloids). In some regions, DS had greater tau burden for a given amyloid level (centiloids) (Figure 1). There was increased spatial distribution of tau throughout the brain for participants with DS compared to CN. In contrast, tau burden was more focal in participants with ADAD with tau primarily elevated in posterior regions (Figure 2).ConclusionWhile tau burden was higher with symptomatic disease for both groups, significant differences existed in the overall amount and spatial spread. Tau spread was greatest in participants with DS and more diffuse compared to ADAD. These results indicate a substantial tau burden is present in DS, and suggest not only anti‐amyloid but also tau‐reducing agents should be considered for treating cognitive decline in adults with DS.
Modeling the temporal evolution of plasma and PET Alzheimer’s disease biomarkers
AbstractBackgroundKnowledge of the temporal evolution among plasma Alzheimer’s biomarkers and PET will inform disease pathophysiology and appropriate implementation of plasma biomarkers (Therneau, NeuroImage 2021; Betthauser, Brain 2022). This study investigates the relative timing of progression of plasma p‐tau181, p‐tau217, GFAP, and amyloid PET on individual and population levels.MethodWe included 957 participants from the Mayo Clinic Study of Aging with clinical diagnoses of cognitively unimpaired (n = 732), MCI (n = 205), and Alzheimer’s clinical syndrome dementia (n = 20). An accelerated failure time (AFT) model was fit with amyloid (PiB) PET, plasma p‐tau217 (Meso Scale Discovery, Lilly), plasma p‐tau181, and GFAP (Simoa, Quanterix HD‐X) as quad‐variate endpoints, and sex, APOE genotype status, and education as covariates. The model output included a per subject adjustment or time‐shift for each biomarker indicating how much earlier or later it was estimated to progress relative to the average participant, the correlation (R) between adjustments for each pair of biomarkers, and the impact of covariates on each biomarker’s timing. Secondly, we estimated progression at a given age for selected cutpoints.ResultTemporal trajectories for each biomarker are shown in Figure 1. Individual‐level adjustments between plasma p‐tau217 and amyloid PET were highly correlated, R = 0.69(0.64‐0.74); how early or late an individual progressed on plasma p‐tau217 explained 48% of the variation in relative timing of amyloid PET progression. Associations of plasma p‐tau181 and GFAP with amyloid PET individual adjustments were moderate and low, respectively (Figure 2). Using the chosen cutpoints, the estimated order of biomarker progression was GFAP, amyloid PET, plasma p‐tau181, and plasma p‐tau217 (Figure 3).ConclusionOn the individual level, the strong association of the relative timing of progression of plasma p‐tau217 and amyloid PET supports that these processes are mechanistically related. The relatively lower associations of the timing of p‐tau181 and GFAP with amyloid PET likely reflect a lower biological association and greater measurement noise for p‐tau181. The individual adjustments, the primary output of this model, are independent of cutpoints. On the population level, relative timing of biomarker change is highly dependent on the cutpoints applied. This true for any analysis that employs cutpoints, regardless of the approach.
Cerebrospinal fluid biomarkers at presentation associate with etiologic diagnosis and treatment responsiveness in patients with rapidly progressive dementia
AbstractBackgroundThe causes of rapidly progressive dementia are heterogeneous, including neurodegenerative, vascular, and autoimmune/inflammatory diseases. Overlap in presenting symptoms and signs, results of cognitive testing, and findings on brain imaging and other common diagnostic tests confounds the etiologic diagnosis, contributing to diagnostic delays, missed opportunities for treatment, and poorer outcomes in patients with RPD. New tools and approaches are needed to improve diagnostic accuracy, with particular emphasis on improving early recognition of patients with potentially treatable causes of RPD.MethodsEstablished and emerging biomarkers of Alzheimer disease neuropathology (Aβ42/40, p‐tau181, p‐tau231), neuroaxonal and neuronal injury (neurofilament light [NfL], VILIP‐1, total tau), neuroinflammation (YKL‐40, sTREM2, GFAP, MCP‐1), and synaptic dysfunction (SNAP‐25, neurogranin) were measured in cerebrospinal fluid obtained at presentation from 78 prospectively accrued patients with RPD due to neurodegenerative (n = 35), vascular (n = 9), and autoimmune/inflammatory (n = 34) diseases, and 72 age‐ and sex‐similar cognitively normal individuals (controls). Causes of RPD were further classified as potentially treatment‐responsive or nonresponsive, referencing the extant literature. Biomarker levels were compared across etiologic diagnoses and by treatment responsiveness, referencing control values. Analyses were adjusted for the effects of age (ANCOVA).ResultsAlzheimer disease biomarkers (low Aβ42/40 and elevated p‐tau181 and p‐tau231) were associated with neurodegenerative causes of RPD (ANCOVA, p = 0.02 p = 0.30, p = 0.15), while high NfL (p = 0.61), low VILIP‐1 (p = 0.009), and elevated markers of inflammation (sTREM2, p = 0.009; YKL‐40, p<0.001) identified patients with autoimmune/inflammatory diseases (Figure). MCP‐1 levels were highest in patients with vascular causes of RPD (p = 0.08). 44 patients (56.4%) had potentially treatment‐responsive causes of RPD. Treatment responsiveness was associated with higher levels of CSF Aβ42/40 (p = 0.003), NfL (p<0.001), sTREM2 (p<0.001) and YKL‐40 (p<0.001); and lower levels of p‐tau‐181 and p‐tau231 (p<0.001, p<0.001) and VILIP‐1 (p<0.001).ConclusionSelected biomarkers measured in CSF at presentation associate with etiologic diagnosis and treatment responsiveness in patients with neurodegenerative, vascular, and autoimmune/inflammatory causes of RPD. Biomarker panels may be adapted to improve recognition of patients with treatment‐responsive causes of RPD early in the symptomatic course when treatments may be most effective.
Comparison of clinicopathologic features of Limbic and Diffuse Transactive Response DNA‐binding Protein 43 pathology in Alzheimer’s disease neuropathologic spectrum
AbstractBackgroundIncreasing evidence suggests that transactive response DNA‐binding protein 43 (TDP‐43) pathology in Alzheimer’s Disease (AD), or AD‐TDP, can be diffuse or limbic‐predominant. Understanding whether diffuse AD‐TDP has genetic, clinical, and pathological features that differ from limbic AD‐TDP could have clinical and research implications. We aimed to better characterize the clinicopathologic features of diffuse AD‐TDP and differentiate it from limbic‐predominant AD‐TDP pathology.MethodThree hundred sixty‐three participants were prospectively recruited and followed in the Mayo Clinic Study of Aging, Alzheimer’s Disease Research Center, and Neurodegenerative Research Group and died between May 1999 and August 2021. All underwent genetic, clinical, neuropsychologic, and neuropathologic evaluations. At postmortem evaluation, they showed Alzheimer’s disease neuropathologic changes and TDP‐43‐immunoreactive inclusions. The distribution of TDP‐43 pathology was assessed using the Josephs 6‐stage scheme. Participants with TDP‐43 stages 1‐3 were classified as Limbic, while those with stages 4‐6 were classified as Diffuse. Neuropathologically defined frontotemporal lobar degeneration cases were excluded. Multivariable logistic regression was used to identify clinicopathological features that predicted diffuse TDP‐43 pathology at postmortem. We hypothesized that the Diffuse group would show impairment in cognitive domains beyond episodic memory and more hippocampal sclerosis.ResultsThe cohort was 61% female and old at onset (median:76 years [IQR:70‐82]) and death (median:88 years [IQR:82‐92]). Fifty‐four percent (n = 197) were classified as Limbic and 46% (n = 166) as Diffuse. A “clinical” multivariate logistic regression fit to 85 participants with all clinical variables of interest showed that later age at onset (OR:1.09, 95%CI:1.01‐1.19;P = 0.03), longer disease duration (OR:1.17, 95%CI:1.02‐1.36;P = 0.03) and higher Neuropsychiatric Inventory scores (OR:1.14, 95%CI:1.01‐1.28;P = 0.03) all independently increased the odds of being Diffuse, while higher Trails Making Test‐B (OR:0.99, 95%CI:0.98‐0.99;P = 0.02) and Block Design Test scores (OR:0.91, 95%CI:0.85‐0.99;P = 0.023) independently decreased the odds of being Diffuse. A “pathology” multivariate logistic regression fit to 233 cases with all neuropathological data revealed that widespread amyloid‐β pathology corresponding to Thal phases 3‐5 all significantly decreased the odds of diffuse pathology by 80‐90%, while hippocampal sclerosis increased it sixfold (OR:6.18, 95% CI:2.93‐13.03;P<0.001).ConclusionsDiffuse AD‐TDP shows clinicopathological features that differ from Limbic AD‐TDP, which could have public health implications relating to treatment and research on AD and dementia.